800医药

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Asymchem Tianjin to convene 2nd H-share AGM on June 10 to vote on A-share buyback authorization

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Baili Tianheng's Innovative Drug SI-B036 Approved for Clinical Trials in Late-Stage Solid Tumors by NMPA

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

515120

510660

<p>In the first quarter of 2026, China's innovative drug industry performed exceptionally well, with the total amount of out-licensing transactions exceeding USD 60 billion, nearly half of the total for the entire year of 2025. The National Medical Products Administration approved 13 innovative drugs for market launch, of which 6 are first-in-class drugs, covering key disease areas. The total number of innovative drugs under research in China reached 4,751, accounting for 33.7% of the global total, with over 45% in several cutting-edge fields. China has become the world's largest country for innovative drugs under research, with transaction volume accounting for 49% of the global total</p>

腾讯新闻 - 财经

GF CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

E Fund CSI Innovative Drugs ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CNI HK Connect Innovative Drugs ETF

ICBCCS CSI Brand Name Drug Industry ETF

CCB Principal CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

China Southern CSI Brand Name Drug Industry ETF

JPMorgan Chase

INNOVENT BIO

Eli Lilly

CSPC PHARMA

AstraZeneca

CITIC Securities Co., Ltd.

CITIC SEC

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

AstraZeneca PLC

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

800医药(000841.SH)

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card